Boehringer, Oxford University and Cumulus to explore brain activity in BPD
The NeuLogiq neuroassessment platform from Cumulus will be leveraged in the BPD patient population.
Therapy Area
AstraZeneca’s Truqap fails in another Phase III trial
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
Biohaven secures $600m financing as it awaits FDA prodrug decision
EC conditionally approves Regeneron’s Lynozyfic for multiple myeloma
France halts Valneva’s chikungunya vaccine use in seniors
J&J’s Tremfya gains EC marketing authorisation for ulcerative colitis
